Purpose The goal of this study is to measure and compare the levels of UII in adipose tissue
and serum in obese and non-obese individuals. Methods This study is to measure and …

Background: Urotensin-II (U-II) is a short cyclic peptide that is widely recognized as one of
the most potent vasoconstrictors. U-II plays a role in the pathophysiology of MS, participating …

Aims Urotensin II (U‐II) is a cyclic peptide that was first isolated from the caudal
neurosecretory system of goby fish. U‐II receptors were detected in the vascular …

Objective: Urotensin-II (U-II) is one of the most vasoconstrictive substrates for the mammals.
Lately, this substrate is thought to be responsible for developing of the neuropsychiatric …

Although urotensin II (UII) has been reported to circulate in human plasma and be raised in
cardiovascular disorders, little, if any, information is available regarding the source of …

Purpose of Investigation: The objectives of this study were to evaluate urotensin 2 (UT-2)
serum levels, a potent vasoconstrictor, in women with irregular menstrual irregularities and …

Background—Human urotensin II (UTN) has potent vasoactive and cardiostimulatory effects,
acting on the G protein–linked receptor GPR14. Myocardial UTN expression is upregulated …

Objective: It is aimed to determine the urotensin II (UII) level and prognostic value in patients
diagnosed with COVID. Materials and Methods: Ninety consecutive patients with COVID-19 …

Abstract Background Increased plasma Urotensin II (UII) levels have been found in adults
with renal diseases. Studies in children are scarce. The objective of the study is to estimate …

The peptide urotensin-II (U-II) has been described as most potent vasoconstrictor identified
so far, but plasma values in humans and its role in cardiovascular pathophysiology are …